China Pharma Holdings (CPHI) Capital Expenditures Growth (3y) (2013 - 2025)
China Pharma Holdings (CPHI) Capital Expenditures Growth (3y) (2013 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | -4.39% |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | -11.01% |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | -0.22% |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 34.19% |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | -8.00% |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | 4.68% |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | -7.72% |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | China Pharma Holdings | 39.71 Mn | 39.41 Mn | 83,566.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 26.34% |
| Sep 30, 2025 | -86.58% |
| Jun 30, 2025 | -26.00% |
| Mar 31, 2025 | 247.41% |
| Dec 31, 2024 | 40.44% |
| Sep 30, 2024 | -26.46% |
| Dec 31, 2023 | 26.40% |
| Sep 30, 2023 | -36.17% |
| Jun 30, 2023 | -26.18% |
| Mar 31, 2023 | -29.28% |
| Dec 31, 2022 | -36.49% |
| Sep 30, 2022 | 174.57% |
| Jun 30, 2022 | 712.52% |
| Mar 31, 2022 | -73.40% |
| Dec 31, 2021 | -26.56% |
| Sep 30, 2021 | 398.89% |
| Dec 31, 2020 | -75.04% |
| Sep 30, 2020 | 155.71% |
| Jun 30, 2020 | 169.46% |
| Mar 31, 2020 | 135.50% |